Bryan D. Smith - Publications

2006 Department of Biochemistry University of Wisconsin, Madison, Madison, WI 

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro-Oncology. PMID 26965451 DOI: 10.1093/neuonc/now030  0.56
2015 Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutloski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell. PMID 26343583 DOI: 10.1016/j.ccell.2015.08.002  0.56
2015 Checco JW, Lee EF, Evangelista M, Sleebs NJ, Rogers K, Pettikiriarachchi A, Kershaw NJ, Eddinger GA, Belair DG, Wilson JL, Eller CH, Raines RT, Murphy WL, Smith BJ, Gellman SH, et al. α/β-Peptide Foldamers Targeting Intracellular Protein-Protein Interactions with Activity in Living Cells. Journal of the American Chemical Society. 137: 11365-75. PMID 26317395 DOI: 10.1021/jacs.5b05896  0.56
2015 Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Molecular Cancer Therapeutics. 14: 2023-34. PMID 26285778 DOI: 10.1158/1535-7163.MCT-14-1105  0.56
2015 Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, et al. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Journal of Medicinal Chemistry. 58: 4165-79. PMID 25965804 DOI: 10.1021/acs.jmedchem.5b00067  0.56
2011 Smith BD, Higgin JJ, Raines RT. Site-specific folate conjugation to a cytotoxic protein. Bioorganic & Medicinal Chemistry Letters. 21: 5029-32. PMID 21570289 DOI: 10.1016/j.bmcl.2011.04.081  0.56
2011 Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.CAN-10-3224  0.56
2011 Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19: 556-68. PMID 21481795 DOI: 10.1016/j.ccr.2011.03.003  0.56
2011 Thiyagarajan N, Smith BD, Raines RT, Acharya KR. Functional and structural analyses of N-acylsulfonamide-linked dinucleoside inhibitors of RNase A. The Febs Journal. 278: 541-9. PMID 21205197 DOI: 10.1111/j.1742-4658.2010.07976.x  0.56
2010 Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, et al. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20: 5793-8. PMID 20800479 DOI: 10.1016/j.bmcl.2010.07.134  0.56
2008 Smith BD, Raines RT. Genetic selection for peptide inhibitors of angiogenin. Protein Engineering, Design & Selection : Peds. 21: 289-94. PMID 18308863 DOI: 10.1093/protein/gzm089  0.56
2006 Smith BD, Raines RT. Genetic selection for critical residues in ribonucleases. Journal of Molecular Biology. 362: 459-78. PMID 16920150 DOI: 10.1016/j.jmb.2006.07.020  0.56
2005 Smith BD, Soellner MB, Raines RT. Synthetic surfaces for ribonuclease adsorption. Langmuir : the Acs Journal of Surfaces and Colloids. 21: 187-90. PMID 15620301 DOI: 10.1021/la0480686  0.56
2003 Smith BD, Soellner MB, Raines RT. Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid). The Journal of Biological Chemistry. 278: 20934-8. PMID 12649287 DOI: 10.1074/jbc.M301852200  0.56
Show low-probability matches.